2006 Press releases
Third Quarter Report 2006
Third Quarter Highlights
- Inclusion in the "first-into-man" study of Clavis Pharma's second cancer drug..
Clavis Pharma and Mount Sinai School of Medicine have entered into collaboration agreement for the development of new cancer drugs
Clavis Pharma ASA, a public development stage pharmaceutical company focusing on cancer therapeutics, and Mount Sinai School of Medicine (MSSM) ...
Second quarter report from Clavis Pharma ASA
With funds secured and new key executives in place, Clavis Pharma is expanding its clinical development programme and business development efforts.
Clavis Pharma ASA - Offering well received
Clavis Pharma ASA-Equity Offering
Clavis Pharma receives clearance to begin Phase I clinical trial with the novel cancer drug CP-4126